Printer Friendly

HAUSER AWARDED MASTER AGREEMENTS FROM THE NATIONAL CANCER INSTITUTE

 BOULDER, Colo., May 27 /PRNewswire/ -- Hauser Chemical Research Inc. (NASDAQ: HAUS) announces it has been awarded two new Master Agreements from the National Cancer Institute (NCI) pre-qualifying Hauser for the large scale isolation and purification of anti-tumor and anti-AIDS agents from natural sources for NCI. The duration of the new agreements is from April 28, 1993 to April 28, 1998. The dollar value of the agreements is dependent upon individual projects.
 Hauser will produce research quantities of natural extracts and purified chemicals derived from natural sources for NCI. The targeted extracts and chemicals will be selected by NCI based upon the known or suspected anti-AIDS or anti-tumor activity of the materials. NCI will use these materials for the completion of advanced screening, toxicological studies and clinical trials.
 According to Dr. Dean Stull, Hauser's chief executive officer, "We are excited about the agreements, and believe that continued involvement in the early development of experimental drugs with NCI will lead to future product opportunities, much like our experience with taxol. We anticipate new work orders from NCI very soon." Hauser began work on taxol in 1988 through a similar Master Agreement with NCI and now is the only commercial producer of Good Manufacturing Practices (GMP) bulk taxol. Taxol(R) received Food and Drug Administration (FDA) approval for treatment of refractory ovarian cancer in December of 1992.
 Hauser Chemical Research is the leader in specialty products from natural sources using its proprietary technologies. These products include natural flavor extracts for the food and beverage industry as well as natural compounds for pharmaceutical, cosmetic and veterinary applications. The company also provides interdisciplinary laboratory testing services, chemical engineering services and contract research and development through its Hauser Laboratories Division. The company is based in Boulder.
 -0- 5/27/93
 /CONTACT: Dean P. Stull or the Investor Relations Department of Hauser Chemical Research, 303-443-4662/
 (HAUS)


CO: Hauser Chemical Research Inc. ST: Colorado IN: MTC SU:

MC -- DV005 -- 2939 05/27/93 12:04 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 27, 1993
Words:328
Previous Article:GOVERNMENT OF KUWAIT SIGNS LOA TO PURCHASE M1A2 ABRAMS FROM U.S. GOVERNMENT
Next Article:SOUTHERN GOURMET PRODUCTS REPORTS ON ANNUAL MEETING
Topics:


Related Articles
HAUSER CHEMICAL RESEARCH INCREASES TAXOL PRODUCTION CAPACITY TO 130 KILOGRAMS PER YEAR
HAUSER TO DOUBLE TAXOL PRODUCTION CAPACITY AT NEW FACILITY
HAUSER NORTHWEST HONORS PRIVATE LANDOWNERS
HAUSER AWARDED NEW PROJECT FROM THE NATIONAL CANCER INSTITUTE FOR A COMPOUND WITH POSSIBLE ANTI-HIV ACTIVITY
HAUSER ANNOUNCES OUTSTANDING FISCAL YEAR END RESULTS
HAUSER EXPANDS AIDS RELATED RESEARCH WITH THIRD NIH GRANT
HAUSER ANNOUNCES COMPLETION OF MICHELLAMINE B PRODUCTION FOR NATIONAL CANCER INSTITUTE
Hauser Signs Agreement to Provide Paclitaxel to a European Pharmaceutical Firm

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters